Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre Sep 28, 2022 4:01pm EDT
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference Aug 31, 2022 4:01pm EDT
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update Aug 08, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 04, 2022 4:01pm EDT
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference Aug 03, 2022 4:01pm EDT
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022 Aug 01, 2022 4:01pm EDT
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS Jul 12, 2022 4:30pm EDT
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022 Jul 06, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 01, 2022 7:57pm EDT
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress Jun 04, 2022 9:00am EDT
